CalciMedica, Inc. (CALC)
OTCMKTS: CALC · Delayed Price · USD
4.010
-0.240 (-5.65%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma.
The company is based in La Jolla, California.
CalciMedica, Inc.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. A. Rachel Leheny Ph.D. |
Contact Details
Address: 505 Coast Boulevard South, Suite 307 La Jolla, California 92037 United States | |
| Phone | 858-952-5500 |
| Website | calcimedica.com |
Stock Details
| Ticker Symbol | CALC |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534133 |
| CUSIP Number | 38942Q202 |
| ISIN Number | US38942Q2021 |
| Employer ID | 45-2120079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | Chief Executive Officer and Director |
| Eric W. Roberts | Chief Business Officer and Vice Chairman of the Board |
| Michael J. Dunn MBA | President and Chief Operating Officer |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder and Chief Scientific Officer |
| Daniel E. Geffken M.B.A. | Interim Chief Financial Officer |
| Cindy Reiedenberg | Accountant |
| John M. Dunn J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 10-K/A | [Amend] Annual report |
| Apr 10, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 424B5 | Filing |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |